When a ministry of health in a low- or middle-income country has to decide whether a new medicine, vaccine, or diagnostic belongs on the national formulary, the honest answer is usually that there is not enough money to fund everything the market offers. Health technology assessment, or HTA, is the discipline built to make that decision defensible rather than arbitrary — a systematic review of a technology’s clinical effectiveness, cost-effectiveness, and broader social and organizational impact, used to inform what a health system pays for. The harder question facing developing nations is not whether to adopt HTA, but which institutional shape it should take: a standing national agency, membership in a regional network, or a lighter partnership arrangement built on borrowed expertise.
What Health Technology Assessment Actually Decides
HTA sits at the point where clinical evidence meets a health ministry’s budget. A properly run process does not simply ask whether a drug or device works; it asks whether the benefit justifies the price relative to everything else the same money could buy, and whether rolling it out is organizationally realistic given workforce, infrastructure, and equity constraints. Universal health coverage commitments have pushed HTA up the policy agenda across the developing world precisely because coverage expansion without a prioritization tool tends to produce either budget overruns or covert rationing at the clinic level. The appeal of HTA is that it makes the rationing explicit, evidence-based, and open to challenge — a meaningfully different governance model from a ministry simply deciding case by case.
The Capacity Problem Behind the Ambition
The gap between wanting HTA and running it is where most developing-nation programs stall. A functioning HTA process needs health economists, epidemiologists, and clinicians who can build cost-effectiveness models, access to reliable local cost and outcomes data, and a legal or administrative mechanism that actually ties the assessment to a funding decision. Many ministries have one or two of those pieces but not all three. Data scarcity is the most persistent constraint: without local unit costs or outcomes registries, an HTA body is forced to import assumptions from wealthier health systems, which weakens the credibility of its conclusions with domestic clinicians and payers alike.
Two Institutional Paths, and a Third That Splits the Difference
Countries that have moved past the capacity gap have generally taken one of three routes, each with a different trade-off between control and speed.
| Model | How It Works | Strength | Limitation |
|---|---|---|---|
| National HTA agency | A standing government body with formal authority over formulary or reimbursement decisions | Direct link between evidence and policy; builds durable domestic expertise | Years and sustained funding required to reach technical maturity |
| Regional network | Multiple countries pool technical staff, methods, and data through a shared body | Spreads scarce expertise across borders; each member gains more capacity than it could build alone | Recommendations are typically advisory; each government still has to act on them nationally |
| Technical assistance partnership | A domestic ministry works with an established external HTA body on a defined program | Fast access to proven methods and international credibility | Depth of capacity left behind depends heavily on how the partnership is structured |
Thailand’s Health Intervention and Technology Assessment Program is the clearest example of the first route: a national HTA organization that has been credited, alongside Brazil’s process, with real cost savings and negotiated drug price reductions, and that now also provides technical support to other governments building their own capacity. Colombia and India are usually cited as the notable exceptions among developing nations for having introduced and institutionalized HTA at the national level on their own timelines.
The regional route looks different. RedETSA, a network spanning fourteen countries and twenty-eight institutions across the Americas, exists specifically because no single smaller health ministry in the region could justify building a full technical bench on its own; instead it offers networking, technical cooperation, and shared capacity-building across members. HTAsiaLink plays a comparable role for HTA agencies across the Asia-Pacific region, giving countries at different stages of maturity a forum to compare methods rather than starting from nothing.
The technical assistance route is where most of the newest entrants sit today. The International Decision Support Initiative was created specifically to expedite HTA institutionalization in Asia and Africa, and the UK’s NICE International has supported technical, management, and communication capacity-building in countries including Myanmar, the Philippines, and Vietnam. Jordan’s experience is a useful variant on this model: private-public partnerships, rather than a bilateral government arrangement, brought regional experts in to train Ministry of Health staff directly. Malawi is at an earlier stage still, with international support currently focused on extending the evidence base and building foundational expertise rather than standing up a formal agency.
Adaptive HTA: The Pragmatic Fourth Option
Not every ministry can wait years for a full agency, a network seat, or a multi-year partnership to mature. Adaptive HTA has emerged as a deliberately lighter-weight response — an expedited, "fit for purpose" methodology that leans on existing international economic evaluations and models rather than commissioning new local analysis for every decision. It trades some precision for speed, and it is explicitly designed for health systems where waiting for a textbook-standard assessment means simply defaulting back to unstructured decision-making in the meantime. A related strategy, sometimes described as aid localization, focuses less on the assessment method and more on where the institutional capacity ends up sitting: building local expertise deliberately rather than leaving each assessment cycle dependent on outside technical assistance, and encouraging collaboration between developing nations directly rather than only between a developing nation and a high-income partner.
Why the Choice of Model Matters
None of these four paths is objectively correct; each answers a different constraint. A country with a stable budget and a long policy horizon has reason to invest in a national agency, since the payoff compounds over time in the form of durable domestic expertise. A smaller health system with a thin technical bench gains more, faster, from a regional network or a well-structured partnership. What the comparison across Thailand, Colombia, Jordan, Malawi, and the RedETSA and HTAsiaLink networks makes clear is that the institutional question is not a formality bolted onto HTA — it determines whether the resulting evidence actually changes what a health system funds, or simply becomes another report that sits alongside the budget decision rather than shaping it. For global health policy audiences watching coverage expansion accelerate across the developing world, that institutional choice is likely to matter as much as the technical method itself.